Latka logo
Imugene Limited logo

Imugene Limitedrevenue & market cap

Sydney, New South Wales, AustraliaFounded 2012

Public company

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients.

imugene.comLinkedInUpdated Sep 28, 2026
Annual revenue
$1.5M
Jun 2026 · Stock Analysis
Market cap
$16.1M
Sep 2026

Imugene Limited revenue

Imugene Limited's annual revenue was $1.5M in June 2026 (Stock Analysis; converted from Australian dollars).

$0
$1M
$2M
$3M
$0
–
$3.1M
$1.5M
20122013–2420252026
ReportedFounded 2012 at $0; every reading has its own bar
All 2 revenue readings, with sources
As ofRevenueSource
Jun 2025$3.1MStock Analysisconverted from Australian dollars
Jun 2026$1.5MStock Analysisconverted from Australian dollars

Imugene Limited market cap

Imugene Limited is a public company. Its market capitalisation was $16.1M in September 2026.

Imugene Limited FAQ

What is Imugene Limited's revenue?

Imugene Limited's annual revenue was $1.5M in June 2026, according to Stock Analysis.

Is Imugene Limited publicly traded?

Yes. Imugene Limited is a public company, with a market capitalisation of $16.1M in September 2026.

Categories

How this page is sourced

2 from public sources. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.

Updated Sep 28, 2026Data disclaimerReport a correctionClaim this profileRun Imugene Limited? Join the podcast